L&K Biomed Approved Original Proposal at General Meeting... "Enhancing Shareholder Value through Aggressive Marketing"

[Asia Economy Reporter Hyungsoo Park] Spinal implant company L&K Biomed held its 14th regular general meeting of shareholders on the 25th.

At the shareholders' meeting, a total of four agenda items were presented and approved as originally proposed: ▲Approval of the 14th financial statements and consolidated financial statements ▲Appointment of a new outside director ▲Approval of the limit on directors' remuneration ▲Approval of the limit on auditors' remuneration.

An L&K Biomed official stated, "Due to the impact of COVID-19, our performance was not good," and added, "This year, the synergy effect will come from L&K Biomed's top-notch technology and the aggressive marketing strategy of the newly established American subsidiary in the U.S. market."

Regarding the appointment of the new outside director, the official said, "The newly appointed outside director, Song Wonsik, is currently serving as Executive Director at Seoul IR Network," and added, "We expect this will help strengthen the IR division and facilitate smooth communication with shareholders and networks."

He continued, "This year marks the first year of management normalization, and we will increase sales and maximize shareholder value through improvements in the management control system and aggressive marketing."

This content was produced with the assistance of AI translation services.